FeesSafety
Pluang+

Fusemachines launches AI consent module in HireFoundry.ai to ease compliance with US state AI hiring laws.

Market News
29 Oct 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Fusemachines launches AI consent module in HireFoundry.ai to ease compliance with US state AI hiring laws.

Fusemachines has introduced a new AI Usage Consent Module in its HireFoundry.ai platform to help enterprises comply with varying AI hiring laws across US states. The module offers adaptable candidate disclosures and consent workflows tailored to state-specific requirements, allowing candidates to opt in or out of AI participation during interviews. This innovation reduces legal complexity for companies hiring nationwide and supports responsible AI use by ensuring transparency and candidate control. Fusemachines aims to simplify AI adoption in hiring while maintaining compliance and recruiter oversight.

Fusemachines' new compliance features in HireFoundry.ai provide context for readers interested in technology innovation, alongside Pluang's snapshot of the US Technology sector as of Oct 29, 2026 18:11 WIB: out of 150 stocks, only 23 rose while 125 fell. Among notable movers, Zscaler Inc (ZS) dropped 6.96% to USD 238.00 with a typical hold time of 42 days and a strong buy order activity of 86%, contrasting with Atlassian Corporation PLC (TEAM) which fell 6.82% to USD 205.10 but saw 100% buy orders over a longer hold time of 65 days. HubSpot Inc (HUBS) also declined 6.69% to USD 231.99 with the longest hold time of 79 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App